CING Stock Price, Cingulate Inc. Quote, Chart

Market Summary

USD0.89+0.05

Market Closed

5.95%

CING Stock Price

View Fullscreen

CING RSI Chart

CING Valuation

Market Cap

1.0M

Price/Earnings (Trailing)

-0.04

EV/EBITDA

-0.04

Price/Free Cashflow

-0.07

MarketCap/EBT

-0.04

CING Price/Earnings (Trailing)

CING Profitability

Return on Equity

342.6%

Return on Assets

-674.08%

Free Cashflow Yield

-1.5K%

CING Fundamentals

CING Earnings

Earnings (TTM)

-23.5M

Earnings Growth (Yr)

-50.59%

Earnings Growth (Qtr)

-15.98%

Breaking Down CING Revenue

Last 7 days

1.1%

Last 30 days

-18.3%

Last 90 days

-76.0%

Trailing 12 Months

-95.8%

How does CING drawdown profile look like?

CING Financial Health

Current Ratio

0.06

CING Investor Care

Shares Dilution (1Y)

65.70%

Diluted EPS (TTM)

-17.52

Tracking the Latest Insider Buys and Sells of Cingulate Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	werth peter j.	acquired	753	0.000727054	1,036,010	-
Sep 15, 2023	callahan jennifer l.	bought	3,348	0.6697	5,000	corporate controller
Aug 11, 2023	werth peter j.	bought	1,000,000	0.5485	1,823,160	-
May 15, 2023	callahan jennifer l.	bought	2,020	1.01	2,000	corporate controller
May 12, 2023	callahan jennifer l.	bought	4,320	1.08	4,000	corporate controller
Dec 16, 2022	schaffer shane j.	bought	10,166	1.0166	10,000	chief executive officer
Dec 14, 2022	callahan jennifer l.	bought	7,467	0.9894	7,548	corporate controller
Dec 14, 2022	schaffer shane j.	bought	13,399	1.01	13,267	chief executive officer
Dec 13, 2022	werth peter j.	bought	28,421	0.9823	28,934	-
Dec 13, 2022	schaffer shane j.	bought	1,750	1.01	1,733	chief executive officer

Which funds bought or sold CING recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	GoalVest Advisory LLC	unchanged	-	-45.00	45.00	-%
Apr 15, 2024	GoalVest Advisory LLC	added	625	52.00	1,276	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-87,218	-	-%
Feb 15, 2024	MERCER GLOBAL ADVISORS INC /ADV	sold off	-100	-22,000	-	-%
Feb 14, 2024	Lynwood Capital Management Inc.	sold off	-100	-8,250	-	-%
Feb 14, 2024	Hudson Bay Capital Management LP	reduced	-50.00	-63,240	6,324	-%
Feb 14, 2024	LPL Financial LLC	sold off	-100	-7,751	-	-%
Feb 14, 2024	SABBY MANAGEMENT, LLC	reduced	-1.16	-76,576,000	16,776,000	0.02%
Feb 14, 2024	Creative Planning	sold off	-100	-7,742	-	-%
Feb 14, 2024	Altium Capital Management LP	unchanged	-	-36,450	8,100	-%

Are Funds Buying or Selling CING?

Are funds buying CING calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CING

No. of Funds

Unveiling Cingulate Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 12, 2024	werth peter j.	19.48%	1,178,108	SC 13D/A
Feb 28, 2024	werth peter j.	19.95%	1,171,055	SC 13D/A
Feb 09, 2024	lind global fund ii lp	9.9%	282,000	SC 13G
Feb 09, 2024	werth peter j.	19.99%	958,440	SC 13D/A
Jan 29, 2024	werth peter j.	19.99%	327,085	SC 13D/A
Jan 04, 2024	schaffer shane j.	3.65%	53,305	SC 13D/A
Jan 04, 2024	werth peter j.	19.99%	327,085	SC 13D/A
Nov 08, 2023	werth peter j.	19.99%	3,977,472	SC 13D/A
Sep 18, 2023	werth peter j.	19.9%	2,839,715	SC 13D/A
Sep 18, 2023	schaffer shane j.	5.7%	990,300	SC 13D/A

Recent SEC filings of Cingulate Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	SC 13D/A	13D - Major Acquisition
Apr 04, 2024	S-8	Employee Benefits Plan
Apr 03, 2024	424B4	Prospectus Filed
Apr 02, 2024	EFFECT	EFFECT
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	POS AM	POS AM

Peers (Alternatives to Cingulate Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Cingulate Inc. News

Latest updates

Cingulate Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet										(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	-40.5%	3,491	5,870	5,227	7,163	11,405	15,377	13,804	18,433	22,886	5,788
Current Assets	-80.1%	579	2,902	2,038	3,753	7,870	11,834	10,102	14,574	18,882	1,790
Cash Equivalents	-97.4%	52.00	1,986	350	1,739	5,356	9,796	8,196	12,614	16,493	1,198
Net PPE	0.6%	2,546	2,531	2,686	2,841	2,905	2,851	2,953	3,054	3,145	3,039
Liabilities	73.6%	10,361	5,967	11,326	7,081	7,523	7,010	1,619	2,414	2,043	4,495
Current Liabilities	78.4%	10,226	5,732	10,995	6,659	7,013	6,406	924	1,631	1,177	3,361
Shareholder's Equity	-Infinity%	-6,869	-	-	82.00	3,882	8,367	12,185	16,019	20,844	1,292
Retained Earnings	-8.1%	-92,943	-86,008	-80,029	-73,413	-69,408	-64,803	-60,776	-56,735	-51,732	-31,022
Additional Paid-In Capital	0.2%	86,074	85,912	73,930	73,494	73,290	73,169	72,963	72,756	72,576	-
Shares Outstanding	-	1,168	-	12,057	11,309	-	-	11,309	11,309	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	40.3%	-2,562	-4,291	-4,603	-3,576	-4,206	-3,399	-4,412	-3,864	-4,622	-2,585	-1,550	-1,674	-
Share Based Compensation	-34.6%	155	236	217	204	206	206	207	182	-	-	-	-	-
Cashflow From Investing	-Infinity%	-186	-	-1*	-37.13	-143	3.00	-2.48	-10.40	-710	-15.77	-22.49	-66.47	-
Cashflow From Financing	-86.2%	815	5,928	3,215	-3.92	-89.78	4,996	-3.74	-3.68	19,910	3,472	1,809	1,351	-

CING Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 15,493,304	$ 8,995,280
General and administrative	7,265,885	8,506,438
Operating loss	(22,759,189)	(17,501,718)
Interest and other expense, net	(775,758)	(174,514)
Loss before income taxes	(23,534,947)	(17,676,232)
Income tax benefit (expense)
Net loss and comprehensive loss	$ (23,534,947)	$ (17,676,232)
Net loss per share of common stock, basic	$ (26.00)	$ (29.35)
Net loss per share of common stock, diluted	$ (26.00)	$ (29.35)
Weighted average number of shares used in computing net loss per share of common stock, basic	905,225	602,340
Weighted average number of shares used in computing net loss per share of common stock, diluted	905,225	602,340

CING Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 52,416	$ 5,356,276
Miscellaneous receivables	14,622	234,432
Prepaid expenses and other current assets	511,556	2,278,944
Total current assets	578,594	7,869,652
Property and equipment, net	2,545,965	2,904,787
Operating lease right-of-use assets	366,877	630,618
Total assets	3,491,436	11,405,057
Current liabilities:
Accounts payable	5,199,105	762,357
Accrued expenses	1,651,519	894,635
Note payable	3,000,000	5,000,000
Finance lease liability, current	17,057	16,053
Operating lease liability, current	358,085	339,755
Total current liabilities	10,225,766	7,012,800
Long-term liabilities:
Finance lease liability, net of current	4,436	21,487
Operating lease liability, net of current	130,663	488,748
Total long-term liabilities	135,099	510,235
Total liabilities	10,360,865	7,523,035
Stockholders’ Equity
Common Stock, $0.0001 par value; 240,000,000 shares authorized and 1,167,520 and 602,640 shares issued and outstanding as of December 31, 2023 and 2022	118	61
Preferred Stock, $0.0001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding as of December 31, 2023 and 2022
Additional Paid-in-Capital	86,073,896	73,290,457
Accumulated deficit	(92,943,443)	(69,408,496)
Total stockholders’ equity	(6,869,429)	3,882,022
Total liabilities and stockholders’ equity	$ 3,491,436	$ 11,405,057

About Cingulate Inc.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

CEO	Dr. Shane J. Schaffer Pharm.D., PharmD
WEBSITE	cingulate.com
INDUSTRY	Biotechnology
EMPLOYEES	15

Cingulate Inc. Frequently Asked Questions

What is the ticker symbol for Cingulate Inc.? What does CING stand for in stocks?

CING is the stock ticker symbol of Cingulate Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cingulate Inc. (CING)?

As of Fri Apr 26 2024, market cap of Cingulate Inc. is 1.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CING stock?

You can check CING's fair value in chart for subscribers.

What is the fair value of CING stock?

You can check CING's fair value in chart for subscribers. The fair value of Cingulate Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cingulate Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CING so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cingulate Inc. a good stock to buy?

The fair value guage provides a quick view whether CING is over valued or under valued. Whether Cingulate Inc. is cheap or expensive depends on the assumptions which impact Cingulate Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CING.